drugset

drugset / Trial / NCT00398099

To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)

NCT00398099 ↗

Phase 3 Completed 30 enrolled Merck Sharp & Dohme LLC

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To collect clinical response data with the use of ertapenem in approved indications.

Timeline

Start: 2005-07
Primary completion: 2006-01
Completion: 2006-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ertapenem	Small molecule	—	—

Indications